{"id":539000,"date":"2021-09-16T07:03:38","date_gmt":"2021-09-16T11:03:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/"},"modified":"2021-09-16T07:03:38","modified_gmt":"2021-09-16T11:03:38","slug":"autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/","title":{"rendered":"Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK"},"content":{"rendered":"<h2>\n&#8211; Allowing global commercial launch capacity for obe-cel (AUTO1)<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">LONDON, Sept.  16, 2021  (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that planning approval has been granted to build the Company\u2019s new manufacturing facility in Stevenage, UK. The 70,000 square foot facility is being built by Merit Holdings Limited as general contractor for the Reef Group, who will lease the facility to Autolus. Global commercial launch capacity for obecabtagene autoleucel (obe-cel) will initially be provided by the existing clinical trial manufacturing facility at The Cell and Gene Therapy Catapult (CGTC) facility, and will then move to the new Autolus facility which will allow for GMP capacity for approximately 2,000 batches a year initially, with scope to expand.<\/p>\n<p align=\"justify\">\u201cStevenage is rapidly becoming one of Europe\u2019s largest clusters for biotechnology and the establishment of our own manufacturing facility will secure global commercial launch capacity for obe-cel,\u201d said Dr. Christian Itin, chief executive officer of Autolus. \u201cWe are excited by the progress we are making with obe-cel for the treatment of adult patients with acute lymphoblastic leukemia (ALL) and expect data from the pivotal FELIX study in 2022.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Autolus Therapeutics plc<\/strong><br \/>\n        <br \/>Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WNjSgS4JTsFUdAgvJTesULYdNbCG-6BdVeG18yug_kqpUk1DiBEkMaU_GZfB1oKoc7OAGdlP6MtNCbvAmPYHoA==\" rel=\"nofollow noopener\" target=\"_blank\">www.autolus.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Obe-cel\u00a0<\/strong><br \/>\n        <br \/>Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies.\u00a0Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, Obe-cel may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the ability of the programmed T cells to engage in serial killing of target cancer cells. In collaboration with our academic partner, UCL, Obe-cel is currently being evaluated in a Phase 1 clinical trial in adult ALL and B-NHL. The company has also progressed Obe-cel to the FELIX study, a potential pivotal study.<\/p>\n<p align=\"justify\">\n        <strong>About <\/strong><br \/>\n        <strong>Obe-cel<\/strong><br \/>\n        <strong>FELIX study<\/strong><br \/>\n        <br \/>The FELIX Phase 1b\/2 clinical trial is enrolling adult patients with relapsed \/ refractory ALL. The trial has a short Phase 1b component prior to proceeding to a single arm Phase 2 clinical trial. The primary endpoint is overall response rate, and the key secondary endpoints include duration of response, MRD negative CR rate and safety. The trial will enroll approximately 100 patients across 30 of the leading academic and non-academic centers in the United States,\u00a0United Kingdom\u00a0and\u00a0Europe.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; and &#8220;believes.&#8221; These statements include, but are not limited to, statements regarding the future clinical development, efficacy, safety and therapeutic potential of obe-cel, including progress, expectations as to the reporting of data, conduct and timing and potential future clinical activity and milestones; expectations regarding the initiation, design and reporting of data from clinical trials. Any forward-looking statements are based on management&#8217;s current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks that Autolus\u2019 preclinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the results of early clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; and the impact of the ongoing COVID-19 pandemic on Autolus\u2019 business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus\u2019 actual results to differ from those contained in the forward-looking statements, see the section titled &#8220;Risk Factors&#8221; in Autolus&#8217; Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 4, 2021, as well as discussions of potential risks, uncertainties, and other important factors in Autolus&#8217; subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.<\/p>\n<p align=\"justify\">\n        <strong>Contact: <\/strong>\n      <\/p>\n<p align=\"justify\">Lucinda Crabtree, PhD<br \/>Vice President, Business Strategy and Planning<br \/>+44 (0)\u00a07587 372 619<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rOrX7K2levhjtVdlc8KSrd05D4o4r5WeE90ZIuHyjQyemTcOVOGDEtcFVaK92ASXzhMtl1ziGZyhagSkyBQ1PUbDs08i8oRmOM-YgjcJphY=\" rel=\"nofollow noopener\" target=\"_blank\">l.crabtree@autolus.com<\/a><\/p>\n<p align=\"justify\">Julia Wilson<br \/>+44 (0) 7818 430877<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0ZwfEcf-SXNVyZY7mhFLiP9y518IfqHhiGX7FoLemcuMbAlDY-jeEIXQnZvKG9e-uI1tH6nU4tGxqkHaXf31dGvC0t2cV35HjFpcuRXpC34=\" rel=\"nofollow noopener\" target=\"_blank\">j.wilson@autolus.com<\/a><\/p>\n<p align=\"justify\">Susan A. Noonan<br \/>S.A. Noonan Communications<br \/>+1-212-966-3650<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hCVyxnc90InLKPy2zb7cj4H3TjUAx9zlYaLF1m0eh8v5P1McEaa2sV62-8CbDZrcwQxsiB8T6jqtwgbaaPxLvqIHYMzJABf2Bt3rjsObS3A=\" rel=\"nofollow noopener\" target=\"_blank\">susan@sanoonan.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNzA4NyM0NDA4Njg4IzIxMTA0Mjk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MWY3ODM3NjctMDgwYS00Nzc3LWFkNWItN2FlYjgzNDNmYTBlLTExMjIwMDA=\/tiny\/Autolus-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Allowing global commercial launch capacity for obe-cel (AUTO1) LONDON, Sept. 16, 2021 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that planning approval has been granted to build the Company\u2019s new manufacturing facility in Stevenage, UK. The 70,000 square foot facility is being built by Merit Holdings Limited as general contractor for the Reef Group, who will lease the facility to Autolus. Global commercial launch capacity for obecabtagene autoleucel (obe-cel) will initially be provided by the existing clinical trial manufacturing facility at The Cell and Gene Therapy Catapult (CGTC) facility, and will then move to the new Autolus facility which will allow for GMP capacity for approximately 2,000 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-539000","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; Allowing global commercial launch capacity for obe-cel (AUTO1) LONDON, Sept. 16, 2021 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that planning approval has been granted to build the Company\u2019s new manufacturing facility in Stevenage, UK. The 70,000 square foot facility is being built by Merit Holdings Limited as general contractor for the Reef Group, who will lease the facility to Autolus. Global commercial launch capacity for obecabtagene autoleucel (obe-cel) will initially be provided by the existing clinical trial manufacturing facility at The Cell and Gene Therapy Catapult (CGTC) facility, and will then move to the new Autolus facility which will allow for GMP capacity for approximately 2,000 &hellip; Continue reading &quot;Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-16T11:03:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNzA4NyM0NDA4Njg4IzIxMTA0Mjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK\",\"datePublished\":\"2021-09-16T11:03:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\\\/\"},\"wordCount\":876,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNzA4NyM0NDA4Njg4IzIxMTA0Mjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\\\/\",\"name\":\"Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNzA4NyM0NDA4Njg4IzIxMTA0Mjk=\",\"datePublished\":\"2021-09-16T11:03:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNzA4NyM0NDA4Njg4IzIxMTA0Mjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNzA4NyM0NDA4Njg4IzIxMTA0Mjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/","og_locale":"en_US","og_type":"article","og_title":"Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK - Market Newsdesk","og_description":"&#8211; Allowing global commercial launch capacity for obe-cel (AUTO1) LONDON, Sept. 16, 2021 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that planning approval has been granted to build the Company\u2019s new manufacturing facility in Stevenage, UK. The 70,000 square foot facility is being built by Merit Holdings Limited as general contractor for the Reef Group, who will lease the facility to Autolus. Global commercial launch capacity for obecabtagene autoleucel (obe-cel) will initially be provided by the existing clinical trial manufacturing facility at The Cell and Gene Therapy Catapult (CGTC) facility, and will then move to the new Autolus facility which will allow for GMP capacity for approximately 2,000 &hellip; Continue reading \"Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-16T11:03:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNzA4NyM0NDA4Njg4IzIxMTA0Mjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK","datePublished":"2021-09-16T11:03:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/"},"wordCount":876,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNzA4NyM0NDA4Njg4IzIxMTA0Mjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/","name":"Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNzA4NyM0NDA4Njg4IzIxMTA0Mjk=","datePublished":"2021-09-16T11:03:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNzA4NyM0NDA4Njg4IzIxMTA0Mjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNzA4NyM0NDA4Njg4IzIxMTA0Mjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/539000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=539000"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/539000\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=539000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=539000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=539000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}